Amicus Therapeutics (NASDAQ:FOLD) will announce its earnings results before the market opens on Monday, November 11th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, meeting the consensus estimate of ($0.34). The business had revenue of $44.13 million for the quarter, compared to analysts’ expectations of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The firm’s revenue for the quarter was up 107.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.33) earnings per share. On average, analysts expect Amicus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:FOLD opened at $8.94 on Friday. The stock has a market cap of $2.26 billion, a P/E ratio of -6.72 and a beta of 1.58. The firm’s fifty day simple moving average is $8.39 and its 200 day simple moving average is $10.88. Amicus Therapeutics has a twelve month low of $7.11 and a twelve month high of $14.61. The company has a quick ratio of 6.97, a current ratio of 7.09 and a debt-to-equity ratio of 0.31.

Several analysts recently weighed in on FOLD shares. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a report on Monday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Amicus Therapeutics in a report on Monday, October 14th. Cowen set a $31.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Amicus Therapeutics in a report on Thursday, October 17th. Finally, BidaskClub upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $17.72.

In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $10.05, for a total transaction of $201,000.00. Following the completion of the transaction, the chief executive officer now owns 770,194 shares of the company’s stock, valued at $7,740,449.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John F. Crowley sold 14,500 shares of the firm’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $8.01, for a total value of $116,145.00. Following the transaction, the chief executive officer now directly owns 735,694 shares of the company’s stock, valued at approximately $5,892,908.94. The disclosure for this sale can be found here. Insiders own 2.50% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

See Also: Asset Allocation, Balancing Your Investments

Earnings History for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.